2009 May;219(2):449-58
Remember: only escalate one compound at a time
Prescription products should stay in original packaging with the pharmacy label and supporting documentation
When taking Semaglutide, you may experience some common side effects, including: Gastrointestinal Issues: Nausea, diarrhea, vomiting, constipation, and abdominal discomfort are frequent, especially when starting treatment or after a dose increase
Research suggests 5-Amino-1MQ may support metabolic health, cellular energy production, NAD+ optimization, and body composition when combined with proper nutrition and exercise
long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
